Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ipsen S.A. ADR (OP: IPSEY )

31.17 UNCHANGED
Streaming Delayed Price Updated: 11:40 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ipsen S.A. ADR

< Previous 1 2 Next >
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Via Benzinga
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
From Ipsen
Via Business Wire
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
From Ipsen
Via Business Wire
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
From Ipsen
Via Business Wire
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
From Ipsen
Via Business Wire
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Ipsen SA (OTC: IPSEY) has 
Via Benzinga
Ipsen to acquire Epizyme, expanding its portfolio in oncology
From Epizyme, Inc.
Via Business Wire
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
From Ipsen
Via Business Wire
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
From Ipsen
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
Via Benzinga
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Ipsen
Via Business Wire
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
From Ipsen
Via Business Wire
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have  
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... 
Via Benzinga
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters
Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... 
Via Benzinga
Ipsen Stock Declines After Pulling Rare Disease Application
Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... 
Via Benzinga
Exposures Product Safety
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as... 
Via Benzinga
Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,... 
Via Benzinga
Ipsen In-Licenses Parkinson's Candidate From IRLAB
Ipsen SA (OTC: IPSEY) and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam. Under the terms of the agreement,... 
Via Benzinga
Here's Why Exelixis Stock Is Dropping Today
The company reported successful clinical trial results, but investors were still disappointed. 
Via The Motley Fool
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
3 Cheap Pharmaceutical Stocks to Grab Now
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
Exposures COVID-19
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.